Acessibilidade / Reportar erro

Melanocytic matricoma: a pigmented lesion on the forehead Study conducted at the General Hospital “Dr. Manuel Gea González”, México City, Mexico.

Dear Editor,

A 74-year-old woman presented to our outpatient dermatology clinic with a 4-year history of an asymptomatic, pigmented tumor located on the forehead. On physical examination, we found a 5 mm, dark brown colored papule, surrounded by an erythematous rim. Past medical history was unremarkable. On dermoscopy, we found blue-gray ovoid nests, ulceration and peripheral telangiectasias (Fig. 1). The tumor was clinically diagnosed as pigmented basal cell carcinoma. A cutaneous biopsy was performed, and the histopathologic study revealed an epithelial, well-circumscribed neoformation that was composed of basophilic cells with hyperchromatic nuclei, a scarce cytoplasm, and prominent nucleoli. Mixed with these basaloid cells, there were multiple cells with basophilic nuclei and eosinophilic cytoplasm that were arranged in small nests. Sparse ghost cells were also found. There were multiple dendritic and pigmented melanocytes as well as areas of compacted keratinization (Fig. 2). Immunohistochemical study with BerEP4 turned positive in basaloid areas. Melanocytic matricoma diagnosis was concluded and a complete tumor resection was performed. The patient remained clinically disease-free during follow-up consultation.

Figure 1
Physical examination. (A) A dark brown-black colored papule. (B) Dermoscopy. Blue-gray ovoid nests and ulceration, surrounded by a 3 mm erythematous and elevated rim.

Figure 2
Histopathology findings (A) Well circumscribed tumor arranged in lobes (Hematoxylin & eosin, 4×). (B) Basaloid and ghost cells with compact keratinization (Hematoxylin & eosin, 10×). (C) Basaloid cells and numerous dendritic melanocytes (Hematoxylin & eosin, 20×). (D) Dendritic pigmented melanocytes (Hematoxylin & eosin, 40×).

Melanocytic matricoma is considered an adnexal tumor with matrical differentiation.11 Carlson JA, Healy K, Slominski A, Mihm MC Jr. Melanocytic matricoma: a report of two cases of a new entity. Am J Dermatopathol. 1999;21:344-9.,22 Rizzardi C, Brollo A, Colonna A, Brutto RL, Melato M. A tumor with composite pilo-folliculosebaceous differentiation harboring a recently described new entity-melanocytic matricoma. Am J Dermatopathol. 2002;24:493-7. This newly described neoformation predominates in males, and it is strongly associated with sun-damaged skin in elderly patients, with a mean age of 71 years at presentation.33 Williams CM, Bozner P, Oliveri CV, Horenstein MG. Melanocytic matricoma: case confirmation of a recently described entity. J Cutan Pathol. 2003;30:275-8.,44 Horenstein MG, Kahn AG. Pathologic quiz case: a 69-year-old man with a brown-black facial papule. Melanocytic matricoma. Arch Pathol Lab Med. 2004;128:e163- Only 32 cases have been reported in international literature. This uncommon tumor is predominantly located on the head, particularly in the nose and preauricular area, but it has also been reported on the neck, trunk, and extremities.44 Horenstein MG, Kahn AG. Pathologic quiz case: a 69-year-old man with a brown-black facial papule. Melanocytic matricoma. Arch Pathol Lab Med. 2004;128:e163- Its classical clinical presentation is described as a small, well-circumscribed, nodular tumor with an asymmetric dark pigmentation.11 Carlson JA, Healy K, Slominski A, Mihm MC Jr. Melanocytic matricoma: a report of two cases of a new entity. Am J Dermatopathol. 1999;21:344-9.,44 Horenstein MG, Kahn AG. Pathologic quiz case: a 69-year-old man with a brown-black facial papule. Melanocytic matricoma. Arch Pathol Lab Med. 2004;128:e163- Melanocytic matricoma is a biphasic tumor that comprises an epithelial component with matrical differentiation, and a melanocytic component with dendritic melanocytes. The epithelial component consists of basaloid cells with scarce cytoplasm, round nuclei, dotted nuclear chromatin, and prominent nucleoli. These basaloid cells might acquire mild to moderate pleomorphism with a slightly elevated mitotic activity, thus denominated matrical and supramatrical cells. These cells show an abrupt or gradual transition to ghost cells. In contrast, the melanocytic component appears as a well-circumscribed arranged nodule that is composed of melanocytes, intermixed with matrical and supramatrical cells, as well as foci of ghost cells. The epithelial component shows positivity for cytokeratin and beta-catenin, whereas dendritic melanocytes are highlighted by HMB-45, S-100, and Melan-A.55 Aranguren-López I, Ibarbia-Oruezabal S, Segués-Merino N. Melanocytic matricoma: a rare tumor that can mimic melanoma. An Bras Dermatol. 2022;97:833-4. Most tumors involve superficial to deeper dermis, without an evident epidermal or adnexal connection.11 Carlson JA, Healy K, Slominski A, Mihm MC Jr. Melanocytic matricoma: a report of two cases of a new entity. Am J Dermatopathol. 1999;21:344-9. The histopathologic and immunohistochemical findings suggest that melanocytic matricoma resembles anagen hair growth. Therefore, melanocytic matricoma is currently classified as a cutaneous adnexal tumor with both follicular and matrical differentiation.44 Horenstein MG, Kahn AG. Pathologic quiz case: a 69-year-old man with a brown-black facial papule. Melanocytic matricoma. Arch Pathol Lab Med. 2004;128:e163-

Clinical differential diagnosis includes basal cell carcinoma, melanoma, and hemangioma, but the main clinical differential diagnosis is pilomatrixoma11 Carlson JA, Healy K, Slominski A, Mihm MC Jr. Melanocytic matricoma: a report of two cases of a new entity. Am J Dermatopathol. 1999;21:344-9. (Table 1).66 Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52:1071-80.

7 Kibbi N, Kluger H, Choi JN. Melanoma: clinical presentations. Cancer Treat Res. 2016;167:107-29.
-88 Russo T, Piccolo V, Ferrara G, Agozzino M, Alfano R, Longo C, et al. Dermoscopy pathology correlation in melanoma. J Dermatol. 2017;44:507-14. This benign cutaneous tumor is found predominantly in young females (average 20 years), localized frequently on the neck and extremities, and it is clinically presented as a multilobulated and firm subcutaneous nodule. In contrast, histopathologic differential diagnosis includes tumors with matrical differentiation, such as pilomatrixoma, pigmented pilomatrixoma, and basal cell carcinoma with matrical differentiation (Table 2).99 Soler AP, Burchette JL, Bellet JS, Olson JA Jr. Cell adhesion protein expression in melanocytic matricoma. J Cutan Pathol. 2007;34:456-60.

Table 1
Differential diagnosis of melanocytic matricoma.44 Horenstein MG, Kahn AG. Pathologic quiz case: a 69-year-old man with a brown-black facial papule. Melanocytic matricoma. Arch Pathol Lab Med. 2004;128:e163-,66 Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52:1071-80..
Table 2
Histopathological differences between melanocytic matricoma, pigmented pilomatrixoma and pigmented basal cell carcinoma with matrical differentiation.44 Horenstein MG, Kahn AG. Pathologic quiz case: a 69-year-old man with a brown-black facial papule. Melanocytic matricoma. Arch Pathol Lab Med. 2004;128:e163-,99 Soler AP, Burchette JL, Bellet JS, Olson JA Jr. Cell adhesion protein expression in melanocytic matricoma. J Cutan Pathol. 2007;34:456-60.,1010 Kyrpychova L, Carr RA, Martinek P, Vanecek T, Perret R, Chottová-Dvořáková M, et al. Basal cell carcinoma with matrical differentiation: clinicopathologic, immunohistochemical, and molecular biological study of 22 cases. Am J Surg Pathol. 2017;41:738-49.

The importance of recognizing this recently described tumor is based on its unknown prognosis and lack of treatment options, besides surgery. Therefore, it is important to consider melanocytic matricoma in elderly, sun-damaged skin patients with a newly discovered pigmented neoplasm, besides pigmented basal cell carcinoma and melanoma, requiring wider surgical margins and a closer follow-up. It is essential to report all melanocytic matricoma cases to establish its clinical course and prognostic features.

  • Financial support

    None declared.
  • Study conducted at the General Hospital “Dr. Manuel Gea González”, México City, Mexico.

References

  • 1
    Carlson JA, Healy K, Slominski A, Mihm MC Jr. Melanocytic matricoma: a report of two cases of a new entity. Am J Dermatopathol. 1999;21:344-9.
  • 2
    Rizzardi C, Brollo A, Colonna A, Brutto RL, Melato M. A tumor with composite pilo-folliculosebaceous differentiation harboring a recently described new entity-melanocytic matricoma. Am J Dermatopathol. 2002;24:493-7.
  • 3
    Williams CM, Bozner P, Oliveri CV, Horenstein MG. Melanocytic matricoma: case confirmation of a recently described entity. J Cutan Pathol. 2003;30:275-8.
  • 4
    Horenstein MG, Kahn AG. Pathologic quiz case: a 69-year-old man with a brown-black facial papule. Melanocytic matricoma. Arch Pathol Lab Med. 2004;128:e163-
  • 5
    Aranguren-López I, Ibarbia-Oruezabal S, Segués-Merino N. Melanocytic matricoma: a rare tumor that can mimic melanoma. An Bras Dermatol. 2022;97:833-4.
  • 6
    Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52:1071-80.
  • 7
    Kibbi N, Kluger H, Choi JN. Melanoma: clinical presentations. Cancer Treat Res. 2016;167:107-29.
  • 8
    Russo T, Piccolo V, Ferrara G, Agozzino M, Alfano R, Longo C, et al. Dermoscopy pathology correlation in melanoma. J Dermatol. 2017;44:507-14.
  • 9
    Soler AP, Burchette JL, Bellet JS, Olson JA Jr. Cell adhesion protein expression in melanocytic matricoma. J Cutan Pathol. 2007;34:456-60.
  • 10
    Kyrpychova L, Carr RA, Martinek P, Vanecek T, Perret R, Chottová-Dvořáková M, et al. Basal cell carcinoma with matrical differentiation: clinicopathologic, immunohistochemical, and molecular biological study of 22 cases. Am J Surg Pathol. 2017;41:738-49.

Publication Dates

  • Publication in this collection
    23 Sept 2024
  • Date of issue
    Sep-Oct 2024

History

  • Received
    12 Feb 2023
  • Accepted
    21 May 2023
Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br